Filing Flows › Health Care › AstraZeneca (AZN)

AstraZeneca (AZN) earnings and revenue breakdown

Latest: Q2 2026 · 6-K filed Jul 27, 2026 · AstraZeneca (AZN) Q2 2026 earnings results →

Q2 2026 Revenue up 9% year over year to $30.7B · 18¢ of every $1 of revenue kept as net profit · operating margin 24.2%

AstraZeneca made $30.7B in Q2 2026 (+9% Y/Y): Oncology $14.1B, BioPharmaceuticals $11.2B, Rare Disease $4.9B. Operating margin 24.2%, net earnings $5.6B. See where every dollar goes — costs, profit and cash — as a Sankey from the 6-K filed Jul 27, 2026.

Revenue$30.7B

Year over year+9%

Operating margin24.2%

Net earnings$5.6B

Operating cash flow—

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $30.7B in Q2 2026, up 9% year over year and up 101% from the previous quarter. Oncology was the largest line at 46% of revenue.

Gross margin was 83.0%, down 0.1 points from a year earlier. Operating profit was $7.4B, a 24.2% margin (down 1.5 points year over year). Of the extra revenue versus a year earlier, 9% reached operating profit, below the 26% margin then. Operating expenses grew 12% against revenue growth of 9%. Net earnings were $5.6B, up 4% year over year. The effective tax rate was 16.7%.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q2 2026	6-K	Jul 27, 2026	$30.7B	+9%	24.2%	$5.6B	—
Q1 2026	6-K	Apr 29, 2026	$15.3B	+12%	27.8%	$3.1B	$4.3B

Charts

Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.